From A.I. to Musk’s Brain Chips, the F.D.A.’s Device Unit Faces Rapid Change (The New York Times)

Dr. Michelle Tarver takes charge of the FDA’s device division amid an era of transformative medical technologies, including AI-driven tools for cancer detection and brain-computer interfaces restoring motor and speech functions. As innovation reshapes healthcare, the FDA faces challenges in ensuring safety while managing increasing industry influence and ethical concerns, particularly following her predecessor’s controversies. The division also grapples with regulating AI transparency and rapid advancements in biotechnology, prompting calls for stronger oversight and more robust frameworks to address the complexities of modern medical devices.